Clinical trials of GH treatment in patients with Turner s syndrome in Japan a consideration of final height
|
|
- Lewis Lewis
- 5 years ago
- Views:
Transcription
1 European Journal of Endocrinology (1997) ISSN Clinical trials of GH treatment in patients with Turner s syndrome in Japan a consideration of final height K Takano 1,6, M Ogawa 2,6, T Tanaka 3,6, K Tachibana 4,6, K Fujita 5,6, N Hizuka 1,6 and The Members of the Committee for the Treatment of Turner s Syndrome 1 Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women s Medical College, Tokyo 162, Japan, 2 Department of Pediatrics, Nagoya University, Nagoya 466, Japan, 3 National Children s Hospital, Tokyo 154, Japan, 4 Kanagawa Children s Medical Center, Kanagawa 232, Japan, 5 Department of Pediatrics, Osaka-City General Hospital, Osaka 534, Japan and 6 The Foundation for Growth Science in Japan, Tokyo 162, Japan (Correspondence should be addressed to K Takano, Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women s Medical College, Tokyo 162, Japan) Abstract Clinical trials of human GH (hgh) therapy in Turner s syndrome were started in Between 1986 and 1990, 362 patients were enrolled; 115 were treated for more than 6 years. The age at the start of treatment ranged from 5 to 18 years (mean 10 years). Fifty-one patients received hgh at a weekly dosage of 0.5 IU/kg and 64 received 1.0 IU/kg by daily s.c. injection. Both treatment groups showed a statistically significant growth increase during the initial 4 years of treatment. The rate of increase in height was significantly greater for the initial 2 years with the high dose than with the low dose. The increases in height over 6 years of treatment (expressed by S.D. score for chronological age) were with 0.5 IU/kg per week and with 1.0 IU/kg per week. To date, 260 patients have stopped GH therapy. In 32% of them, the height attained was above the ¹2 S.D. value for normal girls. In 27%, the growth rate was not sufficient when they stopped treatment. The mean final height (growth rate 1.0 cm/year) of patients treated for more than 6 years was cm (n ¼ 15) with 0.5 IU/kg per week, and cm (n ¼ 15) with 1.0 IU/kg per week. The adult height was improved by GH treatment, although final height did not differ statistically between the two dose regimens. No remarkable adverse events occurred during the treatment. These results indicate that hgh treatment improves the final height in patients with Turner s syndrome. European Journal of Endocrinology Introduction Turner s syndrome is a chromosomal disorder of females involving many physical abnormalities; it includes short stature and slow growth rate. Short stature has been treated with anabolic steroids, low doses of oestrogen, human growth hormone (hgh), or a combination therapy (1 5). Since the successful synthesis of hgh by recombinant DNA technology (6), several investigators have reported the safety and biological activity of recombinant hgh (rhgh) in humans. hgh therapy in Turner s syndrome began systematically several years ago as clinical trials (7 11). Although GH could obviously induce a substantial increase in the rate of increase in height, the long-term outcome in terms of final height is still unclear. Final height data have been requested by the regulatory authority to validate the benefits of GH therapy in Turner s syndrome. The Japanese multicentre trial of GH therapy in Turner s syndrome was started in 1986, and interim results have been reported (8, 12 16). In 1991, the Japanese Ministry of Health and Welfare approved GH treatment only for those patients with Turner s syndrome who had GH deficiency, using a dose of 0.5 IU/kg per week which was the same as that given to patients with GH deficiency (pituitary dwarfism). Some of our patients who fulfilled these criteria were transferred to treatment with GH preparations which became commercially available at that time. Here, we report the results of clinical trials started between 1986 and 1990 in Japan. Most of the patients were included among those reported previously (8, 12 16). We performed the last survey of our clinical trials between May and August in Subjects and methods The number of patients enrolled in the clinical trials of GH treatment from 1986 to 1990 was 362. The criteria for the acceptance into these clinical trials were: sex chromosome analysis indicative of Turner s syndrome; birth body weight more than 2000 g; chronological age more than 5 years; body height less than ¹2 S.D. of that 1997 Society of the European Journal of Endocrinology
2 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 GH treatment in Turner s syndrome final height 139 Figure 1 Age distribution of the patients at the start of hgh treatment with 0.5 IU/kg per week (B, n ¼ 186) and 1.0 IU/kg per week (A, n ¼ 176). of age-matched normal girls; bone age less than 11 years old; and no previous therapy to accelerate the growth rate. Informed consent was obtained from each patient and her parents, and the experimental protocol was approved by the Human Subjects Investigation Committee of the participating medical hospitals. One hundred and eighty-six patients were treated with hgh 0.5 IU/kg per week and 176 were treated with 1.0 IU/kg per week. There were no differences among the groups in chronological age, bone age, height, degree of overweight and growth rate at the start of treatment. Their chronological age ranged from 5 to 18 years (mean 10.0 years; Fig. 1). The weekly dosage was divided into six or seven aliquots and was injected s.c. Vital signs, height and body weight were checked during the treatment, and blood count, urine analysis and laboratory tests including oral glucose tolerance were performed throughout treatment. During the first 3 years, the clinical trials were under the sponsorship of the pharmaceutical company which supplied hgh, but they subsequently came under the control of the Foundation for Growth Science in Japan. Combined oestrogen therapy was not allowed during the first 3 years of clinical trials. Thereafter, oestrogen therapy was started according to the wishes of the individual girl or to the advice of doctors. There is no standard for oestrogen therapy in patients with Turner s syndrome in Japan, but they generally start therapy to induce puberty at about 16 years of age, compared with the age of about 13 years in their European counterparts. The drugs commonly given are conjugated oestrogen (Premalin mg), mestranol (Devocin 0.02 mg), oestriol (Estriel 0.2 mg) and mixtures of oestrogen and progesterone (Duoluton, Sophia). During the 6 years of treatment received by 115 patients, 21 of them were treated with oestrogen and 40 did not receive any oestrogen therapies, even though they did not show any secondary sexual characteristics after the age of 13 years. Growth hormone preparations used in this study were recombinant methionine-free hgh which was kindly provided by Sumitomo Pharmaceutical Co., Ltd (Osaka, Japan), Novo Nordisk Pharmaceuticals, Ltd (Tokyo, Japan) and Eli Lilly Japan K K (Kobe, Japan). Height S.D. score (SDS) and growth rate (SDS) were calculated using the data obtained from Japanese girls with Turner s syndrome described previously (15). The Figure 2 Period of GH treatment (Tx).
3 140 K Takano and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Table 1 Growth rate (cm/year and S.D.) and change in growth rate (DSDS) before and during 6 years of treatment with hgh. Values are means S.D. Before Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 GH 0.5 IU/kg per week (n ¼ 51) cm/year * * * * S.D * * * * ¹ DSDS ¹ ¹ GH 1.0 IU/kg per week (n ¼ 64) cm/year * * * * * S.D. ¹ * * * * * * DSDS * P < 0:05 compared with before treatment; P < 0:05 between two dosages. mean height of Japanese patients with Turner s syndrome was 138 cm. Final height was defined here as a linear growth velocity of 1.0 cm/year or less, measured over 12 months. For statistical analysis, parametric tests were used because the data fitted a normal distribution. The paired t-test was used to compare treatment results with baseline in each treatment group. Results are expressed as the mean S.D. Intergroup comparisons were performed with the unpaired t-test. Correlations between various measurements were calculated by linear regression analysis (Pearson s correlation coefficient). Differences with values of P < 0.05 were considered statistically significant. Results The periods of GH treatment received by the patients are shown in Fig. 2. During the first, second and third years of GH treatment, 14%, 20% and 16% respectively of the patients (50% over 3 years) withdrew from our clinical trials. The number of the patients did not differ statistically between the two dose groups. Thereafter, about 5 6% of the patients per year stopped treatment in both groups of patients. A total of 115 patients were treated for more than 6 years. The growth rates of these 115 patients treated with GH are shown in Table 1. Fifty-one and 64 patients were treated with GH 0.5 IU/kg per week and 1.0 IU/kg per week respectively for more than 6 years. Both treatment groups showed a statistically significant increase in growth rate during the initial 4 years of treatment. The rate of increase in height was significantly greater for the initial 2 years in the high-dose group than in the low-dose group (P < 0.05). The height increase (DSDS) during 6 9 years of treatment is shown in Fig. 3. The increase in height (expressed by SDS score) during treatment was with 0.5 IU/kg per week and with 1.0 IU/kg per week (not statistically different). During 6 9 years of treatment, 54 patients had spontaneous adrenarchae and 17 of them had menstruations. Twenty-one patients were treated with oestrogen, two with very small amounts beginning at the ages of 10 and 11 years; the other 19 received different kinds of oestrogen preparations to induce puberty between the ages of 13 and 20 years (mean 16 years). The remaining 40 patients did not receive oestrogen therapy and did not show any secondary sexual characteristics during the treatment. There were no differences in height increase (DSDS) among the three groups of patients. The actual heights of these patients with Turner s syndrome before and after GH treatment are plotted on the natural growth curves for girls with Turner s syndrome and normal girls in Figs 4 and 5. Totals of 139 and 121 patients treated with 0.5 IU/kg per week and 1.0 IU/kg per week respectively stopped
4 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 GH treatment in Turner s syndrome final height 141 Figure 3 Individual height increase (DSDS) during 6 9 years of hgh treatment with 0 5 IU/kg per week (upper panel, n ¼ 51) and 1.0 IU/kg per week (lower panel, n ¼ 64). X, Puberty (¹); W, spontaneous puberty (+); A, oestrogen-treated. their GH treatment. Data for these patients were analysed according to the age and growth rate when treatment terminated (Table 2). Among the 130 patients younger than 15 years, 52 treated with GH 0.5 IU/kg per week and 38 treated with 1.0 IU/kg per week (69.2% of the age group) stopped GH treatment in spite of a good growth rate of more than 4 cm/year, which is the mean growth rate of 8 9 year old patients with Turner s syndrome. In 33 of the 130 patients (25.4%) younger than 15, the height attained when they stopped GH treatment was above the ¹2 S.D. value for normal girls. In contrast, 65 of the 130 patients (50%) older than 15 years stopped GH treatment in spite of a good growth rate of more than 2 cm/year. In 49 of the 130 patients (37.7%) older than 15, the height attained was above the ¹2 S.D. value for normal girls. Thus 70 of the 260 patients who stopped treatment (26.9%) were assumed to have stopped their GH treatment because of poor growth rates. We analysed the data of patients who reached final adult height (growth rate 1 cm/year). Forty-five patients fulfilled this criterion; their ages ranged from 14 to 22 years, the duration of their treatment was 1 to 9 years and their heights ranged from to cm (Fig. 6). To study the effect of GH treatment on final adult height, we analysed the data of patients who were treated for more than 6 years. The height of the patients treated with GH 0.5 IU/kg per week ranged from to cm (mean cm, n ¼ 15); that of patients treated with 1.0 IU/kg per week ranged from Figure 4 Height of the patients before (left panel) and after (right panel) 6 9 years of 0.5 IU/kg per week hgh treatment (n ¼ 51) plotted on growth curves for normal girls and girls with Turner s syndrome. X, Puberty (¹); W, spontaneous puberty (+); A, oestrogen-treated.
5 142 K Takano and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Figure 5 Height of the patients before (left panel) and 6 9 years after (right panel) 1.0 IU/kg per week hgh treatment (n ¼ 64) plotted on growth curves for normal girls and girls with Turner s syndrome. X, Puberty (¹); W, spontaneous puberty (þ); A, oestrogen-treated to cm (mean cm, n ¼ 15). These two mean values did not differ statistically. The heights did not differ among the four groups of patients of different pubertal status (Fig. 7). The mean height increase (DSDS) was and in groups treated with GH 0.5 IU/kg per week and 1.0 IU/kg per week respectively (difference not statistically significant; Fig. 8). The height increases did not differ among the four groups of different pubertal status. We studied the factors which influenced the final height of these patients (n ¼ 45). There were no correlations between the effect of GH expressed by final height (cm) and height increase (DSDS) on the one hand and the chronological age, bone age, height (cm), growth rate (cm/year, SDS) and overweight (%) at the start of GH treatment on the other. There was a slight correlation between height (SDS) at the start of GH treatment on the one hand and final height (r ¼ 0 46, P < 0.001), and height increase (DSDS) (r ¼ 0 43, P < 0.03) on the other. There were no correlations among the effect of GH and the dose of hgh used, growth rate during the first year of treatment and the duration of GH treatment. During the GH treatment, plasma IGF-I levels increased to similar values in both groups of patients. Basal glucose and immunoreactive insulin levels increased slightly during the treatment, however, glucose intolerance was not observed during the treatment. Haemoglobin A 1 levels were all within the normal range. There were no significant changes in blood count, urine analysis or routine biochemical data during the treatment. Table 2 Height and growth rate at the termination of GH treatment. Values are number (%) of patients who fulfilled the criteria. Chronological age < 15 years Chronological age 15 years GR 4 cm/year GR < 4 cm/year GR 2 cm/year GR < 2 cm/year GH 0.5 IU/kg per week CH < ¹2 S.D. a 39 (75) 18 (72) 21 (70) 22 (69) CH ¹ 2 S.D. 13 (25) 7 (28) 9 (30) 10 (31) Total 52 (100) 25 (100) 30 (100) 32 (100) GH 1.0 IU/kg per week CH < ¹2 S.D. a 26 (68) 14 (93) 22 (63) 16 (48) CH ¹ 2 S.D. 12 (32) 1 (7) 13 (37) 17 (52) Total 38 (100) 15 (100) 35 (100) 33 (100) Total GR, Growth rate; CH, current height. a S.D. of normal girls of the same chronological age.
6 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 GH treatment in Turner s syndrome final height 143 Figure 8 Change in height (DSDS) in patients who reached final height after treatment with hgh for more than 6 years. Line *, mean height of untreated girls with Turner s syndrome (138 cm); line **, 2 S.D. below the mean height of normal girls (148 cm). Figure 6 Height of the patients who reached final height (growth rate 1.0 cm/year) during the clinical trial of GH treatment with 0.5 IU/kg per week (n ¼ 23, upper panel) or 1.0 IU/kg per week (n ¼ 22, lower panel). Symbols indicate the period of GH treatment: B, 3 years; O, 3 6 years; X, > 6 years; line *, mean height of untreated girls with Turner s syndrome (138 cm); line **, 2 S.D. below the mean height of normal girls (148 cm). Discussion Growth hormone treatment in patients with Turner s syndrome has become widespread since adequate amounts of recombinant hgh became available. In Japan, we started clinical trials of hgh treatment in 1984, using recombinant methionyl-hgh (met-hgh) Figure 7 Final height of patients treated with hgh 0.5 IU/kg per week (X, n ¼ 15) or 1.0 IU/kg per week (W, n ¼ 15) for more than 6 years, according to pubertal status (no spontaneous puberty ( ); spontaneous puberty without (M(¹)) and with (M(þ)) menstruation; oestrogen-treated (E 2 -Tx). Line *, mean height of untreated girls with Turner s syndrome (138 cm); line **, 2 S.D. below the mean height of normal girls (148 cm). (7). We observed a growth promoting effect with methgh, but the production of antibody against hgh was observed in 50% of the patients. In the meantime, methionine-free recombinant hgh became available. We then started a multicentre trial of GH using the methionine-free hgh. As we reported previously, this GH had very low antigenicity, not only in patients with GH deficiency, but also in those with Turner s syndrome. We published several papers on the effect of GH treatment in girls with Turner s syndrome, because the clinical trials of GH prepared by each pharmaceutical company started independently. After 3 years of each individual clinical trial, the overall trial was transferred to the surveillance of the Foundation of Growth Science in Japan until the preparation became commercially available. In 1991, the Japanese Ministry of Health and Welfare approved GH treatment only for those patients with Turner s syndrome who had GH deficiency, not on the basis of scientific observation, but from political and economic points of view. As a result, some of the patients who fulfilled the criteria were given commercially available GH preparations and were dropped from our clinical trials. During the clinical trials, adverse events of Creutzfeld-Jakob disease and leukaemia associated with hgh treatment were announced by the mass media. After specialist surveys, it was reported that there was no evidence that hgh treatment increased the incidence of leukaemia. However, these problems may partly explain why about 50% of the patients withdrew from our clinical trial within 3 years. To date, 260 patients (72%) have stopped the clinical trials. Thirty-two percent of them achieved heights within the normal range (current height ¹2 S.D.), but 27% did not attain heights within the normal range and their growth rate was poor. Forty-two percent of the patients withdrew from the clinical trials in spite of heights below the normal range (current height ¹2 S.D.); however, as they were still growing well with hgh, some of them might have continued
7 144 K Takano and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Table 3 Final height of patients with Turner s syndrome treated with hgh, from recent reports. GR FH PAH Duration of treatment FH PAH Reference n (mm/year) (cm) (cm) (years) (cm) 22. Rosenfeld R G et al (USA trial) 23. Van den Broeck J et al. 56 < (five European trials) Attanasio A et al. 6 < ¹0.2 (German trial) 25. Massa G et al. 45 < (Dutch trial) 26. Rochiccioli P et al. 117 < a (French trial) 27. Nilsson K O et al (Swedish trial) n, Number of patients; GR, growth rate; FH: final height; PAH, projected adult height. a Predicted adult height. treatment with commercial GH preparations. We have been following up their treatment after cessation of the clinical trial, how many patients have reached the targetted final height, and how tall they are at present. The main aim of treatment with GH is to improve the final adult height. To assess the effect of GH treatment, an observation period of more than 6 years was needed. In our series of clinical trials, 115 patients were treated for more than 6 years and 30 patients attained near final height (growth rate 1 cm/year). We have reported here the effect of two doses of GH treatment. Growth acceleration was observed with both doses; the effect was greatest during the first year and decreased gradually with duration of treatment. These results were similar to those of other studies (16 21). Decreased effectiveness of GH treatment with increased duration of treatment might be due to resistance of the tissue for GH, IGF-I, or both. However, the mechanism of this phenomenon is not clear at present and requires further study. Of the two doses, the larger increased growth rate to a significantly greater degree only during the initial 2 years of treatment. The current height of the patients showed a large variation in each group of patients and the mean final height did not differ statistically between the two dose groups. However, this result does not imply that a higher dose of hgh is not beneficial. One could use a high dose during the initial 2 or 3 years to let the patients reach the height appropriate to induce puberty at an age similar to that in normal girls. Further observations are required to resolve this question. We analysed the factors which influenced final height and found that the height at the start of treatment was correlated weakly to the effect of GH treatment. However, as the number of patients was small, a further study is required to analyse these factors. No serious adverse events occurred during longterm treatment. Glucose intolerance was not observed in any patient and none had antibody to hgh after 6 years of treatment. Without GH treatment, the mean final height of Japanese girls with Turner s syndrome is 138 cm; the final height was improved by 4 6 cm with GH treatment. These results are similar to those reported by others (22 27). Recently, the final height of patients with Turner s syndrome treated with GH has been reported in the USA and Europe (22 27) (Table 3). The design of the clinical study, the age at the start of GH treatment, the period of GH treatment and the definition of the final height were different in each clinical trial. Some papers reported combination therapy with oxandrolone, oestrogen, or both. Massa et al. (21) studied the influence of induced puberty on the growth-promoting effect of GH and found that ethinyl oestradiol 100 ng/kg per day decelerated the growth rate. In our study, 21 of 115 patients were treated with oestrogen. Most of them were treated to induce puberty after the age of 13 years. During the 6 years of treatment, there were no differences in height increase (DSDS) among the three groups of patients with different pubertal status; furthermore, the final height of patients treated with oestrogen did not differ from that of others. Nilsson et al. (27) reported that the mean net gain of patients treated with combination therapy with oestrogen was 3 4 cm below the projected adult height, but that combined therapy with oxandrolone significantly improved the final height. The patients treated with GH plus oxandrolone had a mean net gain of 8.5 cm over the projected adult height. These results were similar to those reported by Rosenfeld et al. (22). From our observations, we conclude that GH therapy in patients with Turner s syndrome is capable of both accelerating growth and increasing adult height. However, further study is required to enable improved final height and quality of life, by identifying, for example, the ideal age for initiation of GH therapy, the effective dosage and frequency of GH administration, the ideal age for the initiation of anabolic steroid and the effective dosage, and the optimal time and manner of sex steroid replacement therapy.
8 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 GH treatment in Turner s syndrome final height 145 Acknowledgements The authors are very grateful to Sumitomo Pharmaceutical Co., Ltd (Osaka, Japan), Novo Nordisk Pharmaceuticals, Ltd (Tokyo, Japan) and Eli Lilly Japan K K (Kobe, Japan) for supplying the recombinant human growth hormone used in this study. We also thank Novo Nordisk Pharmaceuticals, Ltd (Tokyo, Japan) for helping with statistical analyses. The authors wish to thank all the participating investigators of these studies. References 1 Tanner JM, Whitehouse RH, Hughes PCR & Vince FP. Effect of human growth hormone treatment for 1 to 7 years on the growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner s syndrome and other complaints. Archives of Diseases in Childhood Urban MD, Lee PA, Dorst JP, Plotnick LP & Migeon CJ. Oxandrolone therapy in patients with Turner s syndrome. Journal of Pediatrics Rudman D, Goldsmith M, Kutner M & Blacston D. Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. Journal of Pediatrics Ross J, Cassorla F, Skerda M, Valk I, Loriaux D & Culter G. A preliminary study of the effect of estrogen dose on growth in Turner s syndrome. New England Journal of Medicine Stahnke N. Human growth hormone treatment in short children without growth hormone deficiency. New England Journal of Medicine Goeddel DV, Heyneer HL, Hozumi T, Arentzen R, Itakura K, Yansura DG et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature Takano K, Hizuka N & Shizume K. Treatment of Turner s syndrome with methionyl human growth hormone for six months. Acta Endocrinologica Takano K, Shizume K, Hibi I & the Members of the Committee for the Treatment of Turner s syndrome. Treatment of 203 patients with Turner s syndrome with recombinant human growth hormone for one year: results of a multicentric study in Japan. Acta Endocrinologica Raiti S, Moore WV, Van Vliet G, Kaplan S & the National Hormone and Pituitary Program. Growth-stimulating effects of human growth hormone therapy in patients with Turner syndrome. Journal of Pediatrics Rosenfeld RG, Hintz RL, Johanson AJ, Sherman B, Brasel JA, Burstein S et al. Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner s syndrome. Journal of Pediatrics Vanderschueren-Lodeweyckx M, Massa G, Maes M, Crean M, van Viet G, Heinrichs C et al. Growth promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner s syndrome. Journal of Clinical Endocrinology and Metabolism Takano K, Shizume K, Hibi I & the Members of the Committee for the Treatment of Turner s Syndrome. Treatment of 80 patients with Turner s syndrome with recombinant human growth hormone (YM 17798) for one year: the results of a multicentre study in Japan. Endocrinologica Japonica Takano K, Shizume K, Hibi I & the Members of the Committee for the Treatment of Turner s Syndrome. Treatment of 94 patients with Turner s syndrome with recombinant human growth hormone (SM 9500) for two years: the results of a multicentric study in Japan. Endocrinologica Japonica Takano K, Shizume K, Hibi I & the members of the committee for the treatment of Turner s Syndrome. Treatment of 46 patient with Turner s syndrome with recombinant human growth hormone (YM-17798) for three years: a multicentre study. Acta Endocrinologica Takano K, Shizume K, Hibi I, Suwa S & Okada Y. Cross-sectional growth study of patients with Turner s syndrome. Endocrinologica Japonica Chaussain JL, Gendrel C, Job YC & Ducret JP. Optimization of the dose of growth hormone in girls with Turner syndrome. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Westerlaken CR, Nienhuis HE, Wit JM, Otten BJ, de Muinck Keizer Schrama SMPF, Drayer NM et al. The effect of four years of growth hormone therapy on body stature and proportions in patients with Turner syndrome. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Nilsson KO, Albertsson-Wikland K, Aronson S, Gustafsson J, Hagenäs L, Häger A et al. Long-term results of combination treatment with growth hormone, oxandrolone and ethinyl estradiol in girls with Turner syndrome. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Stahnke N, Stubbe P, Attanasio A, Reinhardt D, Partsch CJ & Sippell WG. GH therapy alone or together with oxandrolone in 212 patients with Turner syndrome (TS): the German experience. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Spoudeas HA, Motta RM, Stanhope R, Hindmarsh PC & Brook CGD. Therapeutic options for promoting growth in the Turner syndrome. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Massa G, Vanderschueren-Lodeweyckx M, on behalf of the Belgian Study Group for Pediatric Endocrinology. Growth promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner syndrome: 4 year results. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Rosenfeld RG, on behalf of the Genentech National Cooperative Study Group. Long-term results of GH therapy in Turner syndrome. In Basic and Clinical Approach to Turner Syndrome, pp Eds I Hibi & K Takano. Amsterdam: Elsevier, Van den Broeck J, Massa GG, Attanasio A, Matranga A, Chaussain JL, Price DA et al. Final height after long-term growth hormone treatmnet in Turner syndrome. Journal of Pediatrics Attanasio A, James D, Reinhardt R & Rekers-Mombarg L. Final height and long-term outcome after growth hormone therapy in Turner syndrome: results of a German multicentre trial. Hormone Research Massa G, Otten BJ, de Muinck Keizer-Schramac SMPF, Delemarrevan de Waal HA, Jansen M, Vulsma T et al. Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Hormone Research Rochiccioli P, Battin J, Bertrand AM, Bost M, Cabrol S, le Bouc Yet al. Final height in Turner syndrome patients treated with growth hormone. Hormone Research Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenäs L et al. Improved final height in girls with Turner s syndrome treatmed with growth hormone and oxandrolone. Journal of Clinical Endocrinology and Metabolism Received 28 November 1996 Accepted 20 March 1997
Final Height in Patients with Turner Syndrome after
Clin Pediatr Endocrinol 1997; 6(Suppl 10), 51-57 Copyright (C) 1997 by The Japanese Society for Pediatric Endocrinology Final Height in Patients with Turner Syndrome after Treatment with GH Kazue Takano,
More informationKAZUE TAKANO, KAZUO SHIZUME, ITSURO HIBI and Members of Committee for the Treatment of Pituitary Dwarfism in Japan
Endocrinol. Japon. 1988, 35 (3), 477-484 A Comparison of Subcutaneous and Intramuscular Administration of Human Growth Hormone (hgh) and Increased Growth Rate by Daily Injection of hgh in GH Deficient
More informationDose Effects of Growth Hormone during Puberty
Puberty Horm Res 2003;60(suppl 1):52 57 DOI: 10.1159/000071226 Dose Effects of Growth Hormone during Puberty Paul Saenger Department of Pediatrics, Division of Pediatric Endocrinology, Childrens Hospital
More informationTwenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome
Twenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome MARIA CORAZON R. VILLADOLID, KAZUE TAKANO, NAOMI HIZUKA, KUMIKO ASAKAWA, IZUMI SUKEGAWA, REIKO HORIKAWA AND KAZUO SHIZUME
More informationand LHRH Analog Treatment in
Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National
More informationShort-term Study of Biosynthesized hgh in Man
Endocrinol. Japon. 1983, 30 (1), 79-84 Short-term Study of Biosynthesized hgh in Man KAZUE TAKANO, NAOMI HIZUKA, KAZUO SHIZUME, KUMIKO ASAKAWA AND MEGUMI KOGAWA Department of Medicine, Tokyo Women's Medical
More informationSomatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More informationEffect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome
ORIGINAL ARTICLE Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome Ping-Yi Hsu, Yi-Ching Tung, Wen-Yu Tsai,* Jing-Sheng Lee, Pei-Hung Hsiao Background/Purpose: Short stature
More informationTreatment of Idiopathic Pituitary Dwarfism with Methionyl Human Growth Hormone
Endocrinol. Japon. 1983, 30 (4), 523-527 Treatment of Idiopathic Pituitary Dwarfism with Methionyl Human Growth Hormone KAZUE TAKANO1, KAZUO SHIZUME1, NAOMI HIZUKA1, ITSURO HIBI2, KIYOHIKO KATO3, HITOSHI
More informationThe New England Journal of Medicine EFFECT OF GROWTH HORMONE TREATMENT ON ADULT HEIGHT OF CHILDREN WITH IDIOPATHIC SHORT STATURE.
EFFECT OF GROWTH HORMONE TREATMENT ON ADULT HEIGHT OF CHILDREN WITH IDIOPATHIC SHORT STATURE RAYMOND L. HINTZ, M.D., KENNETH M. ATTIE, M.D., JOYCE BAPTISTA, PH.D., AND ALEX ROCHE, PH.D., FOR THE GENENTECH
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationX/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Prediction of Long-Term Response to Recombinant Human
More informationTHE MAIN CHARACTERISTICS of Turner syndrome
0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(9):4168 4174 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/jc.2002-022040 Late or Delayed Induced or
More informationThe science behind igro
The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts
More informationOriginal. Tsuyoshi Isojima 1), 2), 3), Tomonobu Hasegawa 1), 4), Susumu Yokoya 1), 5) 1), 6) and Toshiaki Tanaka
2017, 64 (9), 851-858 Original The response to growth hormone treatment in prepubertal children with growth hormone deficiency in Japan: Comparing three consecutive years of treatment data of The Foundation
More informationGrowth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
Sotos and Tokar International Journal of Pediatric Endocrinology 2014, 2014:15 RESEARCH Open Access Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison
More informationA lthough it is assumed that growth hormone (GH) secretion
215 ORIGINAL ARTICLE High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature G A Kamp, J J J Waelkens, S
More informationAdult height after GH therapy in 188 Ullrich Turner syndrome patients: results of the German IGLU Follow-up Study 2001
European Journal of Endocrinology (2002) 147 625 633 ISSN 0804-4643 CLINICAL STUDY Adult height after GH therapy in 188 Ullrich Turner syndrome patients: results of the German IGLU Follow-up Study 2001
More informationRunning title: Growth hormone coverage for idiopathic short stature
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationAdult height of prepubertal short children born small for gestational age treated with GH
European Journal of Endocrinology (2005) 152 835 843 ISSN 0804-4643 CLINICAL STUDY Adult height of prepubertal short children born small for gestational age treated with GH Myriam Rosilio, Jean-Claude
More informationHyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea
Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku
More informationGrowth and metabolic consequences of growth hormone treatment in prepubertal short normal children
Archives of Disease in Childhood 1994; 71: 21-26 Southampton University Hospitals Trust, Tremona Road, Southampton S9 4XY, Department of Child Health E S McCaughey J Mulligan L D Voss Department of Paediatrics
More informationGrowth Hormone plus Childhood Low-Dose Estrogen in Turner s Syndrome
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Growth Hormone plus Childhood Low-Dose Estrogen in Turner s Syndrome Judith L. Ross, M.D., Charmian A. Quigley, M.B., B.S., Dachuang
More informationGrowth and Development in Turner Syndrome
Growth and Development in Turner Syndrome Edna Roche Consultant Paediatric Endocrinologist, National Children s Hospital, AMNCH and the University of Dublin Trinity College Growth in Turner Syndrome Short
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationDate: 24 April-2007 Trial ID: GHTUR/E/2 Version: 2 Integrated Clinical Trial Report Status: Final ICTR Synopsis Page: 1 of 5
ICTR Synopsis Page: 1 of 5 Synopsis TITLE OF TRIAL INDUCTION OF PUBERTY WITH 17 Β-ESTRADIOL IN GIRLS WITH TURNER SYNDROME. AN OPEN RANDOMISED TRIAL TRIAL CODE: GHTUR/E/2 INVESTIGATORS IN TOTAL, 35 PRINCIPAL
More informationBirth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years
European Journal of Endocrinology (2000) 142 460 465 ISSN 0804-4643 CLINICAL STUDY Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age
More informationPUBLICATIONS Abstracts and publications on the psychological data available.
Page 1 of 9 Synopsis TITLE OF TRIAL : The Effects of Biosynthetic Human Growth Hormone Treatment in the Management of Children with Familial Short Stature. Protocol B: A Comparative Evaluation of Growth
More informationPFIZER INC. PROTOCOL TITLE: Growth hormone therapy in short children after renal transplantation for chronic renal failure in Germany.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationExercise as a screening test for growth hormone deficiency in children
Archives of Disease in Childhood, 1973, 48, 508. Exercise as a screening test for growth hormone deficiency in children K. A. LACEY, A. HEWISON, and J. M. PARKIN From the Royal Victoria Infirmary, Newcastle
More informationPhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSomavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT )
Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT02068521) George Bright 1, Wayne V. Moore 2, Huong Jil Nguyen 3, Gad B. Kletter 4, Bradley
More informationAnnalisa Deodati, research fellow, Stefano Cianfarani, associate professor
Molecular Endocrinology Unit- DPUO, Bambino Gesù Children s Hospital Rina Balducci Center of Pediatric Endocrinology, Tor Vergata University, Rome, Italy Correspondence to: S Cianfarani, Department of
More informationPubertal Development in Japanese Boys
Clin Pediatr Endocrinol 1993; (SuPP13): 7-14 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Pubertal Development in Japanese Boys Kenji Fujieda, M.D., Ph. D. Department of Pediatrics,
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationEffects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects
NOTE Effects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects KAZUE TAKANOI,2, NAOMI HIZUKA1,2, KUMIKO ASAKAWA1,2 IZUMI SUKEGAWA1,2, KAZUO SHIZUME2
More informationMoral assessment of growth hormone therapy for children with idiopathic short
3tournal ofmedical Ethics 1997; 23: 305-309 Moral assessment of growth hormone therapy for children with idiopathic short stature Marcel Verweij and Frank Kortmann Abstract The prescription ofgrowth hormone
More informationEuropean Journal of Endocrinology (2003) ISSN
European Journal of Endocrinology (2003) 149 425 432 ISSN 0804-4643 CLINICAL STUDY Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children
More informationTechnology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188
Human growth hormone (somatropin) for the treatment of growth failure in children Technology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188 NICE 2017. All rights reserved. Subject
More informationThree-Year Growth Response to Growth Hormone Treatment in Very Young Children Born Small for Gestational Age Data from KIGS
ORIGINAL ARTICLE Endocrine Care Three-Year Growth Response to Growth Hormone Treatment in Very Young Children Born Small for Gestational Age Data from KIGS Margaret C. S. Boguszewski, Anders Lindberg,
More informationRelationship between Plasma (IGF-l) Levels and Body Mass. Insulin-like Growth Factor Index (BMI) in Adults
Endocrine Journal 1993, 40 (1), 41-45 Relationship between Plasma (IGF-l) Levels and Body Mass Insulin-like Growth Factor Index (BMI) in Adults HIROYuKI YAMAMOTO AND YUZURU KATO First Division, Department
More informationMonitoring of childhood growth has been a part of. Screening of Turner Syndrome with Novel Auxological Criteria Facilitates Early Diagnosis
JCEM ONLINE Advances in Genetics Endocrine Care Screening of Turner Syndrome with Novel Auxological Criteria Facilitates Early Diagnosis Antti Saari, Ulla Sankilampi, Marja-Leena Hannila, Marja-Terttu
More informationand Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects
Serum Follicular - Stimulating Hormone and Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects ROBERT PENNY, THOMAS P. FOLEY, JR., and ROBERT
More informationTHE 6TH MIDDLE EUROPEAN WORKSHOP ON PAEDIATRIC ENDOCRINOLOGY (MEWPE 1999)
27 THE 6TH MIDDLE EUROPEAN WORKSHOP ON PAEDIATRIC ENDOCRINOLOGY (MEWPE 1999) Emmersdorf, Austria, November 19-21, 1999 MEWPE 1999 ORGANIZING COMMITTEE: H. FRISCH WIEN (AUSTRIA), CHAIRPERSON 1999 J. LÉBL
More informationEfficacy and safety of oxandrolone in growth hormonetreated girls with Turner syndrome
2 Efficacy and safety of oxandrolone in growth hormonetreated girls with Turner syndrome Leonie A. Menke, Theo C.J. Sas, Sabine M.P.F. de Muinck Keizer-Schrama, Gladys R.J. Zandwijken, Maria A.J. de Ridder,
More informationGrowth Hormone in Turner Syndrome. V.V. Khadilkar, A.V. Khadilkar, M. Nandy*, G.B. Maskati
Brief Reports Growth Hormone in Turner Syndrome V.V. Khadilkar, A.V. Khadilkar, M. Nandy*, G.B. Maskati From the Growth and Pediatric Endocrine Unit, Hirabai Cowasji Jehangir Medical Research Institute,
More informationJudith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction
Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year
More informationOriginal article Central Eur J Paed 2018;14(1):68-72 DOI /p
Original article Central Eur J Paed 2018;14(1):68-72 DOI 10.5457/p2005-114.201 Growth hormone treatment in children born small for gestational age: One center s experience Sandra Stanković 1, Saša Živić
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationHow to approach a child with growth concern
How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand
More informationHormones. BIT 230 Walsh Chapter 8
Hormones BIT 230 Walsh Chapter 8 Hormones Regulatory molecules Affect all areas of metabolism Endocrine- hormones travel via the bloodstream to its target cell: true hormone Modern definition- any regulatory
More informationGrowth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain
Lundberg et al. BMC Endocrine Disorders (2015) 15:84 DOI 10.1186/s12902-015-0080-8 RESEARCH ARTICLE Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Open Access Elena Lundberg
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationMelatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders
Melatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders Fideleff G., Suárez M., Boquete HR, Azaretzky M., Sobrado P., Brunetto O*, Fideleff HL Endocrinology
More informationResponse to three years of growth hormone therapy in girls with Turner syndrome
Original article http://dx.doi.org/10.6065/apem.2013.18.1.13 Ann Pediatr Endocrinol Metab 2013;18:13-18 Response to three years of growth hormone therapy in girls with Turner syndrome Hong Kyu Park, MD
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended
Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Genotropin/Genotropin Miniquick (somatropin) DK/W/0008/pdWS/007 Marketing
More informationTRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST
TRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST DISCLOSURE No potential conflict of interest OBJECTIVES Review timing considerations for
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationFailure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency
Arch Dis Child 999;8:3 7 3 Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency H Mitchell, M T Dattani, V Nanduri, P C Hindmarsh, M A Preece, C G D Brook London Centre for Paediatric Endocrinology,
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationLee et al. International Journal of Pediatric Endocrinology 2012, 2012:22
Lee et al. International Journal of Pediatric Endocrinology 2012, 2012:22 RESEARCH Open Access Comparison of response to 2-years growth hormone treatment in children with isolated growth hormone deficiency,
More informationbiosynthetic human growth hormone in man A double-blind cross-over study
Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man A double-blind cross-over study J. O. L. J\l=o/\rgensen, A. Flyvbjerg, J. Dinesen H. Lund,
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationZohreh Karamizadeh, MD; Anis Amirhakimi*, MD; Gholamhossein Amirhakimi, MD
Original Article Iran J Pediatr Jun 2014; Vol 24 (No 3), Pp: 293-299 Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationCaretropin. Daewoong Recombinant Human Growth Hormone. Recombinant Escherichia coli. Growth hormone deficiency
Caretropin Daewoong Recombinant Human Growth Hormone Active ingredient Host cell Indication Formulation Administration Somatropin Recombinant Escherichia coli Growth hormone deficiency 1. Lyophilized powder
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationFinal height in isolated GH deficiency type 1A: effects of 5-year treatment with IGF-I
European Journal of Endocrinology (2001) 144 379±383 ISSN 0804-4643 CLINICAL STUDY Final height in isolated GH deficiency type 1A: effects of 5-year treatment with IGF-I M F Messina, F De Luca, M Wasniewska,
More informationStandard Growth Curves in Prader-Willi Syndrome in Japan
Clin Pediatr Endocrinol 1993;2 (1): 39-43 Copyright (C)1993 by The Japanese Society for Pediatric End ocrinology Standard Growth Curves in Prader-Willi Syndrome in Japan Toshiro Nagai, Yutaka Tsuchiya,
More informationEffect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
Biomedical Research 2017; 28 (15): 6813-6817 ISSN 0970-938X www.biomedres.info Effect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationResearchPoint Global, Inc., Austin, TX; 8 Versartis, Inc, Menlo Park, CA
3-Year Update of the Phase 2a and Long-term Safety Studies (VERTICAL and VISTA) of Somavaratan (VRS-317), a Long-acting rhgh for the Treatment of Pediatric Growth Hormone Deficiency Bradley S. Miller 1,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationOZGROW Report 2009/2010
OZGROW Report 2009/2010 GH therapy in Australia As of May 2010 there are 1636 children receiving GH treatment in Australia under the PBS. The Department of Health and Ageing s (DoHA) indication for GH
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationJean-Claude Carel, Emmanuel Ecosse, Marc Nicolino, Maïté Tauber, Juliane Leger, Sylvie Cabrol, Irène Bastié-Sigeac, Jean-Louis Chaussain, Joël Coste
Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry Jean-Claude
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationMonitoring treatment in congenital adrenal
Archives of Disease in Childhood, 1989, 64, 1235-1239 Monitoring treatment in congenital adrenal hyperplasia S APPAN, P C HINDMARSH, AND C G D BROOK Endocrine Unit, Middlesex Hospital, London SUMMARY We
More informationElements for a Public Summary
Page 3 of 7 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Growth hormone deficiency occurs when the pituitary gland does not produce enough growth hormone.. Growth hormone
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationGROWTH-REDUCTIVE THERAPY IN CHILDREN WITH MARFAN SYNDROME
GROWTH-REDUCTIVE THERAPY IN CHILDREN WITH MARFAN SYNDROME L. ROZENDAAL, MD, S. LE CESSIE, PHD, J. M. WIT, MD, PHD, R. C. M. HENNEKAM, MD, PHD, AND THE DUTCH MARFAN WORKING GROUP* Objectives To determine
More informationPeter A Lee 1*, Judith Ross 2, John A Germak 3 and Robert Gut 3
Lee et al. International Journal of Pediatric Endocrinology 2012, 2012:15 RESEARCH Open Access Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies:
More informationIntervention: The children were randomized to either a standard (43 g/kg d) or individualized ( g/kg d) GH dose.
ORIGINAL ARTICLE Endocrine Care Growth Hormone (GH) Dosing during Catch-Up Growth Guided by Individual Responsiveness Decreases Growth Response Variability in Prepubertal Children with GH Deficiency or
More informationPeter A. Lee 1*, Judith L. Ross 2,3, Birgitte Tønnes Pedersen 4, Primoz Kotnik 5, John A. Germak 6 and Henrik T. Christesen 7
Lee et al. International Journal of Pediatric Endocrinology (2015) 2015:17 DOI 10.1186/s13633-015-0015-1 RESEARCH Open Access Noonan syndrome and Turner syndrome patients respond similarly to 4 years growth-hormone
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationGrowth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A
Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/71147
More informationThe somatopause. What stops our growth and diminishes GH secretion?
The somatopause What stops our growth and diminishes GH secretion? What extends or stops statural growth? Statural growth is extended if the early growth rate is slowed underfed adolescents grow for a
More informationComparison of weight- vs body surface area-based growth hormone dosing for children: implications for response
Clinical Endocrinology (2014) 80, 384 394 doi: 10.1111/cen.12315 ORIGINAL ARTICLE Comparison of weight- vs body surface area-based growth hormone dosing for children: implications for response Ian P. Hughes*,
More informationCritical Growth Phases for Adult Shortness
American Journal of Epidemiology Copyright 2000 by The Johns Hopkins University chool of Hygiene and Public Health All rights reserved Vol. 2, o. 2 Printed in U..A. Critical Growth Phases for Adult hortness
More informationThe effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome
5 The effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome Leonie A. Menke, Theo C.J. Sas, Theo Stijnen, Gladys R.J. Zandwijken, Sabine M.P.F. de Muinck Keizer-Schrama,
More information